

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Unlocking the future of precision medicine:
The untapped power of RNA - RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”
- Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime - Surviving cancer is often not a patient’s most challenging battle